This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cue Biopharma (CUE) Catches Eye: Stock Jumps 5.2%
by Zacks Equity Research
Cue Biopharma (CUE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Cue Biopharma, Inc. (CUE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Cue Biopharma, Inc. (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cue Biopharma, Inc. (CUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Cue Biopharma, Inc. (CUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cue Biopharma, Inc. (CUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Cue Biopharma, Inc. (CUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: ThermoGenesis, 21Vianet, Livongo Health, Cue Biopharma and Sharps Compliance
by Zacks Equity Research
Zacks.com featured highlights include: ThermoGenesis, 21Vianet, Livongo Health, Cue Biopharma and Sharps Compliance
The Zacks Analyst Blog Highlights: Cue Biopharma, PJT Partners, Avenue Therapeutics, SpartanNash and Gaia
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cue Biopharma, PJT Partners, Avenue Therapeutics, SpartanNash and Gaia
5 Stocks With Recent Price Strength to Tap Market Rally
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
5 Top Small-Cap Stocks Braving Coronavirus Bloodbath
by Nalak Das
A handful of small-cap stocks have skyrocketed defying the coronavirus-induced market mayhem and extreme volatility.
Should You Buy Cue Biopharma (CUE) Ahead of Earnings
by Zacks Equity Research
Cue Biopharma (CUE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Cue Biopharma, Inc. (CUE) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Cue Biopharma, Inc. (CUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Farmers National, Independent Bank, First Financial Bankshares, HarborOne and Cue Biopharma
by Zacks Equity Research
Zacks.com featured highlights include: Farmers National, Independent Bank, First Financial Bankshares, HarborOne and Cue Biopharma
5 Stocks to Make the Most of New Analyst Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Zacks.com featured highlights include: Independent Bank, HarborOne, Horizon Technology Finance and Cue Biopharma
by Zacks Equity Research
Zacks.com featured highlights include: Independent Bank, HarborOne, Horizon Technology Finance and Cue Biopharma
4 Stocks in Focus as New Analysts Show Interest
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Alnylam Provides Preliminary Q4 Sales for Onpattro & Givlaari
by Zacks Equity Research
Alnylam (ALNY) announces preliminary results for the fourth quarter and 2019 and provides other updates.
Ultragenyx's Gene Therapy Positive in Genetic Disorder Study
by Zacks Equity Research
Shares of Ultragenyx (RARE) rise 23.4% after releasing positive top-line data from the phase I/II study of its gene therapy candidate DTX301 for the treatment of OTC deficiency.
The Zacks Analyst Blog Highlights: EverQuote, Cassava Sciences, Fulgent Genetics, Teekay Tankers and Cue Biopharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: EverQuote, Cassava Sciences, Fulgent Genetics, Teekay Tankers and Cue Biopharma
5 Stocks to Soar in 2020 After Solid Gains in 2019
by Zacks Equity Research
U.S. stocks rallied to attained fresh all-time highs in 2019, as the momentum continued in 2020. Here are five stocks that are poised to grow.
Are You Looking for a Top Momentum Pick? Why Cue Biopharma, Inc. (CUE) is a Great Choice
by Zacks Equity Research
Does Cue Biopharma, Inc. (CUE) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 Biotech Stocks That Have More Than Doubled This Year
by Ekta Bagri
The biotech sector has had a good run in 2019 on the back of ongoing M&A activities and positive pipeline updates.
The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech
5 Biotech Stocks Up More Than 100% This Year So Far
by Indrajit Bandyopadhyay
The biotech sector recovers on the back of rising M&A activities and pipeline successes in 2019 after a dismal 2018. Here we discuss five biotech companies recording impressive growth.
Here's Why Cue Biopharma, Inc. (CUE) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Cue Biopharma, Inc. (CUE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Cue Biopharma, Inc. (CUE) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Cue Biopharma, Inc. (CUE).
What Makes Cue Biopharma, Inc. (CUE) a New Strong Buy Stock
by Zacks Equity Research
Cue Biopharma, Inc. (CUE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).